CO2022016156A2 - Redirección del tropismo de las cápsides de aav - Google Patents

Redirección del tropismo de las cápsides de aav

Info

Publication number
CO2022016156A2
CO2022016156A2 CONC2022/0016156A CO2022016156A CO2022016156A2 CO 2022016156 A2 CO2022016156 A2 CO 2022016156A2 CO 2022016156 A CO2022016156 A CO 2022016156A CO 2022016156 A2 CO2022016156 A2 CO 2022016156A2
Authority
CO
Colombia
Prior art keywords
tropism
redirection
aav capsid
capsid proteins
adeno
Prior art date
Application number
CONC2022/0016156A
Other languages
English (en)
Spanish (es)
Inventor
Mathieu E Nonnenmacher
Jinzhao Hou
Wei Wang
Matthew Child
Shaoyong Li
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of CO2022016156A2 publication Critical patent/CO2022016156A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2022/0016156A 2020-05-13 2022-11-11 Redirección del tropismo de las cápsides de aav CO2022016156A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023927P 2020-05-13 2020-05-13
US202063122300P 2020-12-07 2020-12-07
PCT/US2021/025061 WO2021230987A1 (en) 2020-05-13 2021-03-31 Redirection of tropism of aav capsids

Publications (1)

Publication Number Publication Date
CO2022016156A2 true CO2022016156A2 (es) 2023-01-26

Family

ID=75639982

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0016156A CO2022016156A2 (es) 2020-05-13 2022-11-11 Redirección del tropismo de las cápsides de aav

Country Status (14)

Country Link
US (3) US20230203102A1 (https=)
EP (1) EP4149955A1 (https=)
JP (2) JP7731909B2 (https=)
KR (1) KR20230022175A (https=)
CN (1) CN116096734A (https=)
AU (1) AU2021273447B2 (https=)
BR (1) BR112022023106A2 (https=)
CA (1) CA3182970A1 (https=)
CO (1) CO2022016156A2 (https=)
IL (1) IL298001A (https=)
MX (1) MX2022014256A (https=)
PE (1) PE20230767A1 (https=)
TW (1) TWI900553B (https=)
WO (1) WO2021230987A1 (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110689A2 (en) * 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3861010A1 (en) 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
WO2020102645A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
CN116096734A (zh) 2020-05-13 2023-05-09 沃雅戈治疗公司 Aav衣壳的向性的重定向
EP4185608A4 (en) * 2020-07-23 2024-08-21 University of Florida Research Foundation, Inc. INSULIN RECEPTOR-MEDIATED ENHANCEMENT OF GENE TRANSFER
WO2022174000A2 (en) 2021-02-12 2022-08-18 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240384242A1 (en) * 2021-09-03 2024-11-21 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
MX2024004217A (es) 2021-10-08 2024-06-26 Dyno Therapeutics Inc Variantes de cápside y métodos de uso de estas.
MX2024004936A (es) 2021-11-02 2024-05-08 Voyager Therapeutics Inc Variantes de capsides de aav y sus usos.
WO2023092002A2 (en) * 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis and disorders associatedwith the spinal cord
EP4433490A2 (en) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
TW202334181A (zh) 2021-11-17 2023-09-01 美商航海家醫療公司 Aav蛋白殼變異體及其用途
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4469585A2 (en) 2022-01-25 2024-12-04 Voyager Therapeutics, Inc. Baculovirus expression system
EP4473001A1 (en) * 2022-02-01 2024-12-11 The Broad Institute, Inc. Adeno-associated viral vectors and uses thereof
CA3249551A1 (en) 2022-02-08 2023-08-17 Voyager Therapeutics, Inc. AAV Capsid Variants and Their Uses
CN119836431A (zh) * 2022-04-04 2025-04-15 维克多瑞私人有限公司 重组aav衣壳蛋白
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023220476A2 (en) * 2022-05-13 2023-11-16 The Broad Institute, Inc. Adeno-associated viral vectors and uses thereof
WO2023225564A1 (en) * 2022-05-18 2023-11-23 The Broad Institute, Inc. Engineered viral capsids with increased stability and methods of use thereof
WO2023235791A1 (en) 2022-06-02 2023-12-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
AR129733A1 (es) 2022-06-28 2024-09-25 Voyager Therapeutics Inc Variantes de cápsides de aav y sus usos
AR129843A1 (es) 2022-07-06 2024-10-02 Voyager Therapeutics Inc Variantes de la cápside de aav y usos de estas
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024055020A2 (en) * 2022-09-09 2024-03-14 The Regents Of The University Of California Reprogramming tropism via displayed peptides tiling receptor-ligands
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. TAU PROTEIN BINDING COMPOUNDS
WO2024086747A1 (en) 2022-10-19 2024-04-25 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
KR20250131772A (ko) 2022-11-13 2025-09-03 알렉시온 파마 인터내셔널 오퍼레이션즈 리미티드 전두측두엽 치매에 대한 유전자 요법
CN118420721A (zh) * 2023-01-31 2024-08-02 上海朗昇生物科技有限公司 一种组织嗜性的腺相关病毒衣壳及其用途
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
TW202502803A (zh) 2023-03-10 2025-01-16 美商戴諾治療公司 衣殼多肽及其使用方法
CN120660140A (zh) * 2023-03-27 2025-09-16 浙江大学 氨基酸序列的生成与筛选方法及其系统
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2024226790A1 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
EP4705324A1 (en) 2023-05-02 2026-03-11 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024229167A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2024229173A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2024229164A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
EP4705487A2 (en) 2023-05-03 2026-03-11 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to frataxin deficiency
PE20260124A1 (es) 2023-05-03 2026-01-16 Voyager Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos relacionados con la deficiencia de cdkl5
WO2024229389A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4705488A1 (en) 2023-05-04 2026-03-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025038430A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025038805A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025038796A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025038802A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025038795A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
AR133562A1 (es) 2023-08-16 2025-10-08 Voyager Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina
TW202525832A (zh) 2023-08-31 2025-07-01 美商戴諾治療公司 衣殼多肽及其使用方法(二)
CN119569833A (zh) * 2023-09-06 2025-03-07 北京锦篮基因科技有限公司 靶向骨骼肌的aav衣壳蛋白变体及其用途
CN117264912A (zh) * 2023-09-25 2023-12-22 中国科学院深圳先进技术研究院 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
CN121925426A (zh) * 2023-09-26 2026-04-24 凯特治疗学股份有限公司 肝脏去靶向衣壳
WO2025072698A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Aav9 vectors and capsid polypeptides for use in treating cns disorders
WO2025122548A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025122644A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2025122530A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025122536A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
TW202540436A (zh) 2023-12-05 2025-10-16 美商航海家醫療公司 用於治療與共濟蛋白(frataxin)缺陷相關之病症之組合物及方法
WO2025122543A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025122532A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025137219A1 (en) 2023-12-21 2025-06-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025147436A1 (en) 2024-01-03 2025-07-10 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025194082A1 (en) * 2024-03-15 2025-09-18 The Children's Medical Center Corporation Compositions and methods for delivering nucleic acids to podocytes
WO2025207954A1 (en) * 2024-03-27 2025-10-02 General Medicines Llc Compositions and methods for improved adeno-associated viral gene therapy
CN118324853B (zh) * 2024-04-03 2025-03-14 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2025214359A1 (en) * 2024-04-09 2025-10-16 Hangzhou Jiayin Biotech Ltd. A novel aav variant
WO2025235734A2 (en) 2024-05-09 2025-11-13 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2026012095A1 (en) * 2024-06-21 2026-01-15 Westlake Genetech. Ltd. Adeno-associated virus variant capsids
WO2026010722A1 (en) 2024-07-03 2026-01-08 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2026050402A1 (en) * 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2640638B1 (fr) 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
AU3097399A (en) 1998-03-20 1999-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
FR2786478B1 (fr) 1998-11-30 2000-12-22 Commissariat Energie Atomique Confinement du cesium et/ou du rubidium dans des ceramiques apatitiques
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
WO2000075353A1 (en) 1999-06-02 2000-12-14 Trustees Of The University Of Pennsylvania Compositions and methods useful for production of recombinant viruses which require helper viruses
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
AU1071701A (en) 1999-09-29 2001-04-30 Trustees Of The University Of Pennsylvania, The Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
EP1373527A1 (en) 2001-04-06 2004-01-02 CropDesign N.V. The use of double and opposite recombination sites for the single step cloning of two dna segments
EP2017338A1 (en) 2001-05-24 2009-01-21 Genzyme Corporation Muscle-specific expression vectors
AU2002359284A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US6845866B2 (en) 2002-10-10 2005-01-25 N. Henning Zieger Dispenser
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
WO2005017101A2 (en) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Avian adenoassociated virus (aaav) and uses thereof
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
SI3235827T1 (sl) 2003-06-19 2021-05-31 Genzyme Corporation AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2005001103A2 (en) 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
WO2005072364A2 (en) 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
EP2311967B1 (en) 2005-10-20 2017-09-20 UniQure IP B.V. Improved AAV vectors produced in insect cells
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
ES2385679T3 (es) 2006-08-24 2012-07-30 Virovek, Inc. Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
JP5531225B2 (ja) 2008-07-09 2014-06-25 株式会社東芝 X線管用ターゲットおよびそれを用いたx線管、x線検査装置ならびにx線管用ターゲットの製造方法
DE102008060558B4 (de) 2008-12-04 2013-09-26 Eduard Buzetzki Verfahren zum katalytischen Cracken von Pflanzenölen und tierischen Fetten
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US9163261B2 (en) 2010-02-22 2015-10-20 Koteswara Rao KOLLIPARA Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer
EP2547781A4 (en) 2010-03-17 2014-04-23 Anaptysbio Inc PROCESS FOR PRODUCING TRANSCRIPTION PRODUCTS USING CRYPTIC SPLICE SITES
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US10415056B2 (en) 2010-11-10 2019-09-17 Fred Hutchinson Cancer Research Center Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
HRP20171334T1 (hr) 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013096955A1 (en) 2011-12-23 2013-06-27 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
US9644205B2 (en) 2012-04-25 2017-05-09 The Regents Of The University Of California Synthetic promoter for modulating gene expression
US9636370B2 (en) 2012-09-28 2017-05-02 The University Of North Carolina At Chapel Hill AAV vectors targeted to oligodendrocytes
EP2940131B1 (en) 2012-12-25 2019-02-20 Takara Bio Inc. Aav variant
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
JP6396988B2 (ja) 2013-03-15 2018-09-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合性aavベクターのための方法および組成物
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
EP3134522B1 (en) 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
IL248102B (en) 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016005001A1 (en) 2014-07-11 2016-01-14 Huawei Technologies Co., Ltd. Network device, user device and methods of access signal broadcast
BR112017005892A2 (pt) 2014-09-24 2017-12-12 Hope City variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
AU2015335923B2 (en) 2014-10-21 2021-04-29 University Of Massachusetts Recombinant AAV variants and uses thereof
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
WO2016081811A1 (en) 2014-11-21 2016-05-26 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
WO2016126857A1 (en) 2015-02-03 2016-08-11 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
CA2977355A1 (en) 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases
CN106032540B (zh) 2015-03-16 2019-10-25 中国科学院上海生命科学研究院 CRISPR/Cas9核酸内切酶体系的腺相关病毒载体构建及其用途
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
EP3280451B8 (en) 2015-04-08 2019-09-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Viral gene therapy as treatment for cholesterol storage disease or disorder
WO2017015102A1 (en) 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells
BR112018003665A2 (en) 2015-09-28 2018-09-25 The University Of North Carolina At Chapel Hill methods and compositions for antibody evasion viral vectors
WO2017066764A2 (en) 2015-10-16 2017-04-20 William Marsh Rice University Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
WO2017083722A1 (en) 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
US10240145B2 (en) 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
CN106884014B (zh) 2015-12-16 2020-11-13 北京五加和基因科技有限公司 腺相关病毒反向末端重复序列突变体及其应用
US10179176B2 (en) 2016-02-16 2019-01-15 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
EP3423154B1 (en) 2016-03-01 2021-05-05 Intraop Medical Corporation Low energy electron beam radiation system that generates electron beams with precisely controlled and adjustable penetration depth useful for therapeutic applications
EP3827812B1 (en) 2016-07-29 2025-10-29 The Regents of the University of California Adeno-associated virus virions with variant capsid and methods of use thereof
US20190262373A1 (en) 2016-08-16 2019-08-29 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
US20200316221A1 (en) 2016-10-13 2020-10-08 University Of Massachusetts Aav capsid designs
EP3558393A4 (en) 2016-12-22 2020-11-11 Oregon Health & Science University ADENO-ASSOCIATED VIRAL VECTORS
CN108330147A (zh) 2017-01-20 2018-07-27 上海吉凯基因化学技术有限公司 一种重组腺相关病毒载体生产工艺的建立
US11680275B2 (en) * 2017-06-06 2023-06-20 University Of Massachusetts Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome
MX2020000244A (es) 2017-06-27 2020-09-28 Regeneron Pharma Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas.
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Aavを送達するための組成物および方法
SG11202002276VA (en) 2017-09-20 2020-04-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
BR112020016699A2 (pt) 2018-02-28 2020-12-15 The University Of North Carolina At Chapel Hill Métodos e composições para vetores de vírus de evasão de anticorpos
JP2021523702A (ja) 2018-05-04 2021-09-09 オレゴン ヘルス アンド サイエンス ユニバーシティ ヒト抗aav2カプシドポリクローナル抗体エピトープ
WO2019216932A1 (en) * 2018-05-07 2019-11-14 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
SG11202011151VA (en) 2018-05-15 2020-12-30 Univ Washington Compositions and methods for reducing spliceopathy and treating rna dominance disorders
TW202015742A (zh) 2018-05-15 2020-05-01 美商航海家醫療公司 投遞腺相關病毒(aav)之組成物和方法
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
CN112703198B (zh) * 2018-07-11 2025-05-30 布里格姆妇女医院 用于跨血脑屏障递送试剂的方法和组合物
US20210277418A1 (en) 2018-08-03 2021-09-09 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
US12281321B2 (en) * 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
EP3861010A1 (en) 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CN113395975A (zh) 2018-11-20 2021-09-14 宾夕法尼亚州大学信托人 用于靶向血脑屏障的组合物和方法
WO2020132455A1 (en) 2018-12-21 2020-06-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2020154324A1 (en) 2019-01-22 2020-07-30 Ix Layer Inc. Systems and methods for access management and clustering of genomic or phenotype data
EP3917945A4 (en) 2019-01-30 2023-02-08 The Broad Institute Inc. ADVANCED ADENO-ASSOCIATED VIRUS (AAVS) TARGETED DELIVERY SYSTEMS
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
EP3715358A1 (en) 2019-03-28 2020-09-30 Universität zu Köln Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
TW202102526A (zh) 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
AU2020271108A1 (en) 2019-04-11 2021-11-11 California Institute Of Technology Virus compositions with enhanced specificity in the brain
EP3959226A2 (en) 2019-04-26 2022-03-02 Sangamo Therapeutics, Inc. Engineering aav
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
WO2020223280A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
WO2021025995A1 (en) 2019-08-02 2021-02-11 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
US20220403414A1 (en) 2019-10-16 2022-12-22 Wuxi Apptec (Shanghai) Co., Ltd. Novel aav variant
EP4431524A3 (en) 2019-12-04 2024-12-18 The Board Of Trustees Of The Leland Stanford Junior University Enhancing blood-brain barrier drug transport by targeting endogenous regulators
WO2021202651A1 (en) 2020-04-01 2021-10-07 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
IL297391A (en) 2020-04-20 2022-12-01 Tenaya Therapeutics Inc An adeno-associated virus with an engineered capsid
AU2021264061A1 (en) 2020-05-01 2022-12-01 Massachusetts Institute Of Technology Engineered central nervous system compositions
US12209251B2 (en) 2020-05-05 2025-01-28 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
CN116096734A (zh) 2020-05-13 2023-05-09 沃雅戈治疗公司 Aav衣壳的向性的重定向
CN116390934A (zh) 2020-05-26 2023-07-04 塑造治疗公司 功能性aav衣壳的高通量工程化
CA3192600A1 (en) 2020-08-21 2022-02-24 Capsida, Inc. Adeno-associated virus compositions having preferred expression levels
WO2022076750A2 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Recombinant adeno-associated viruses for cns or muscle delivery
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4322974A4 (en) 2021-04-13 2025-06-25 Capsida, Inc. Adeno-associated virus compositions having increased brain enrichment
EP4322976A4 (en) 2021-04-13 2025-06-25 Capsida, Inc. AAV COMPOSITIONS WITH HIGH EXPRESSION LEVELS IN THE BRAIN
EP4323013A4 (en) 2021-04-13 2025-06-25 Capsida, Inc. SELECTED AAV COMPOSITIONS WITH PREFERRED BRAIN ENRICHEMENT
WO2022221421A2 (en) 2021-04-13 2022-10-20 Capsida, Inc. Aav compositions with high brain expression for treating mucopolysaccharidosis ii
WO2022235702A1 (en) 2021-05-04 2022-11-10 California Institute Of Technology Recombinant aavs for delivery to central nervous system and brain vasculature
EP4373834A4 (en) 2021-07-23 2025-06-04 California Institute of Technology VIRAL VECTORS FOR ENHANCED ULTRASOUND-INDUCED DELIVERY TO THE BRAIN
WO2023044306A1 (en) 2021-09-14 2023-03-23 California Institute Of Technology Aav capsid variants
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20240382617A1 (en) 2021-09-21 2024-11-21 Capsida Biotherapeutics, Inc. Virus compositions to efficiently target the nervous system and the lungs
MX2024004936A (es) 2021-11-02 2024-05-08 Voyager Therapeutics Inc Variantes de capsides de aav y sus usos.
US20250001007A1 (en) 2021-11-16 2025-01-02 California Institute Of Technology Adeno-associated virus compositions having preferred heart and skeletal muscle enrichment
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023092002A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis and disorders associatedwith the spinal cord
TW202334181A (zh) 2021-11-17 2023-09-01 美商航海家醫療公司 Aav蛋白殼變異體及其用途
EP4433490A2 (en) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
CA3249551A1 (en) 2022-02-08 2023-08-17 Voyager Therapeutics, Inc. AAV Capsid Variants and Their Uses
CN119095865A (zh) 2022-03-03 2024-12-06 加州理工学院 用于跨越血脑屏障的组合物和方法
CA3254570A1 (en) 2022-03-24 2023-09-28 Capsida, Inc. ADENE-ASSOCIATED VIRUS COMPOSITIONS WITH INCREASED CARDIAC ENRICHEMENT
KR20240162556A (ko) 2022-03-24 2024-11-15 캡시다, 인크. 바람직한 뇌 풍부화를 갖는 선택된 aav 조성물
JP2025512333A (ja) 2022-04-11 2025-04-17 テナヤ セラピューティクス, インコーポレイテッド 操作されたカプシドを伴うアデノ随伴ウイルス
WO2023215546A2 (en) 2022-05-06 2023-11-09 Capsida, Inc. Adeno-associated virus compositions having increased brain enrichment
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
KR20250017219A (ko) 2022-05-17 2025-02-04 캡시다, 인크. 바람직한 뇌, 척수, 및/또는 심장 발현 수준을 갖는 선택된 아데노-연관 바이러스 조성물
WO2023235791A1 (en) 2022-06-02 2023-12-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US20250255989A1 (en) 2022-06-16 2025-08-14 Capsida, Inc Adeno-associated virus compositions having increased brain enrichment and/or heart enrichment
EP4540395A1 (en) 2022-06-16 2025-04-23 Capsida, Inc. Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
AR129733A1 (es) 2022-06-28 2024-09-25 Voyager Therapeutics Inc Variantes de cápsides de aav y sus usos
AR129843A1 (es) 2022-07-06 2024-10-02 Voyager Therapeutics Inc Variantes de la cápside de aav y usos de estas
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. TAU PROTEIN BINDING COMPOUNDS
CN120265647A (zh) 2022-10-19 2025-07-04 卡西达生物疗法股份有限公司 具有优选脑富集和低肝富集的腺相关病毒组合物
WO2024086747A1 (en) 2022-10-19 2024-04-25 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
AU2023367210A1 (en) 2022-10-27 2025-05-01 California Institute Of Technology Targets for receptor-mediated control of therapeutic biodistribution and efficacy
KR20250131772A (ko) 2022-11-13 2025-09-03 알렉시온 파마 인터내셔널 오퍼레이션즈 리미티드 전두측두엽 치매에 대한 유전자 요법
TW202502803A (zh) 2023-03-10 2025-01-16 美商戴諾治療公司 衣殼多肽及其使用方法
WO2024226790A1 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP4705324A1 (en) 2023-05-02 2026-03-11 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024229164A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2024229173A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
CN121127597A (zh) 2023-05-03 2025-12-12 沃雅戈治疗公司 用于治疗与葡糖苷酰鞘氨醇酶β1缺陷相关的病症的组合物及方法
EP4705487A2 (en) 2023-05-03 2026-03-11 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to frataxin deficiency
WO2024229167A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
PE20260124A1 (es) 2023-05-03 2026-01-16 Voyager Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos relacionados con la deficiencia de cdkl5
WO2024229389A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4705488A1 (en) 2023-05-04 2026-03-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
AU2024274127A1 (en) 2023-05-15 2025-11-13 Sangamo Therapeutics, Inc. Fitness maturation of engineered aav capsid stac-102
AU2024271436A1 (en) 2023-05-15 2025-11-13 Sangamo Therapeutics, Inc. Engineered blood brain barrier penetrant aav capsids
WO2025038802A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025038430A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025038796A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025038795A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
AR133562A1 (es) 2023-08-16 2025-10-08 Voyager Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina
WO2025038805A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025147436A1 (en) 2024-01-03 2025-07-10 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof

Also Published As

Publication number Publication date
US11859200B2 (en) 2024-01-02
PE20230767A1 (es) 2023-05-09
AU2021273447A1 (en) 2022-12-08
JP7731909B2 (ja) 2025-09-01
JP2023525810A (ja) 2023-06-19
US20220042044A1 (en) 2022-02-10
US12577588B2 (en) 2026-03-17
WO2021230987A1 (en) 2021-11-18
CN116096734A (zh) 2023-05-09
KR20230022175A (ko) 2023-02-14
CA3182970A1 (en) 2021-11-18
AU2021273447B2 (en) 2026-03-05
US20230203102A1 (en) 2023-06-29
IL298001A (en) 2023-01-01
EP4149955A1 (en) 2023-03-22
BR112022023106A2 (pt) 2023-01-17
US20240200097A1 (en) 2024-06-20
TWI900553B (zh) 2025-10-11
JP2025173511A (ja) 2025-11-27
TW202208397A (zh) 2022-03-01
MX2022014256A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
CO2022016156A2 (es) Redirección del tropismo de las cápsides de aav
WO2020028751A3 (en) Aav variants with enhanced tropism
MX2024004936A (es) Variantes de capsides de aav y sus usos.
MX2024014624A (es) Variantes de capsides de aav y sus usos
WO2021025995A9 (en) Aav variants with enhanced tropism
MX2024009660A (es) Variantes de capside de aav y usos de las mismas.
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
MX2021013266A (es) Nuevas capsides de aav y composiciones que las contienen.
BR112022022644A2 (pt) Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas
MX2020003176A (es) Variantes de capsides de virus adenoasociados y metodos de uso de estas.
MX2020006764A (es) Una proteína de la cápside de raav modificada para terapia génica.
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
MX2023009627A (es) Capsides variantes de virus adenoasociados y metodos de uso de las mismas.
MX388331B (es) Variantes de virus adenoasociado y métodos de uso de estas
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
AU2018298422A1 (en) Novel nucleic acid molecules
CO2020013699A2 (es) Composiciones aav, métodos de fabricación y métodos de uso
BR112022000724A2 (pt) Proteínas de capsídeo de aav modificado para tratamento de doença artrítica
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
MX2022013462A (es) Variantes, formulaciones y metodos adeno-asociados para suministro pulmonar.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
BR112017024283A2 (pt) vacinas contra a dengue